Semantic Scholar uses AI to extract papers important to this topic.
Interpatient variability in the pharmacokinetics (PK) of sunitinib is high. Single nucleotide polymorphisms (SNPs) in PK… Expand SummaryIntroduction Sunitinib is a multikinase inhibitor active in various cancers types including renal cancers and endocrine… Expand CONTEXT
Treatment of refractory adrenocortical carcinoma (ACC) is not established. Animal experiments pointed toward adrenal… Expand Sunitinib malate (Sutent®, Pfizer Inc.) is a multitargeted tyrosine kinase inhibitor that inhibits tumor cell proliferation and… Expand This phase I, open‐label, single‐dose study evaluates the effects of severe renal impairment and end‐stage renal disease (ESRD… Expand A rapid and sensitive ultra performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) method has been developed and… Expand Purpose: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and… Expand BACKGROUND
Sunitinib was approved by the US Food and Drug Administration (FDA) on January 26, 2006, for the treatment of… Expand PurposeSunitinib, an oral multitargeted tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FLT3, KIT, and RET, is currently… Expand The effect of food on the oral bioavailability of sunitinib malate (SU11248, an oral, multi-targeted tyrosine kinase inhibitor… Expand